Verve rises as FDA lifts clinical hold on trial for lead gene editing therapy
23/10/2023 12:42
** Shares of genetic medicines developer Verve Therapeutics
VERV.O rise 13.2% to $10.50 premarket
** Company says U.S. FDA has lifted clinical hold and
cleared its application to start trial of lead investigational
gene editing therapy VERVE-101
** VERVE-101 is being studied for the treatment of
heterozygous familial hypercholesterolemia (HeFH), an inherited
condition that increases the risk of heart diseases
** VERV plans to begin the process of activating U.S.
clinical trial sites for early stage trial
** Company is scheduled to report interim clinical data from
the early stage trial at a conference on Nov. 12, 2023
** Up to last close, stock down ~52% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))